Drug · DIN 02456915
COPAXONE
PREFILLED SYRINGE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since August 26, 2016; first marketed August 26, 2016.
- Drug Identification Number (DIN)
- 02456915
- Company (DIN owner)
- Teva Canada LimitedToronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Glatiramer acetate L03AX13
- Class
- Human
- Record last updated
- July 31, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| GLATIRAMER ACETATE | 40 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- August 16, 2016: NOC 18369Supplement to a New Drug Submission (SNDS) · New clinical studies to support a new dose and a new dosage regimen
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “copaxone”. A notice may cover another product or only some lots: read it to see what it covers.
- Important Safety Information on COPAXONE (glatiramer acetate) and the Risk of Anaphylactic Reactions Which May Occur at Any Time Following Initiation of TreatmentAugust 21, 2025 · Drugs · New safety information - Product safety - Adverse reaction
Other DINs named COPAXONE
- DIN 02245619 · Marketed
- DIN 02233014 · Cancelled Post Market
- DIN 02512173 · Approved